Hearing Aids
Also known as: Ears, Aural, Auditory, Acoustic
Methodology & AI Transparency ⓘ
Hearing Aids Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: A hearing aid is a small electronic device that you wear in or behind your ear.
- 2 Real-world patient consensus: Diagnostic registry J35.7: Hearing Aids is managed within ENT & Hearing (aka Ears).
- 3 Typical cash cost range: Primary evaluation for Hearing Aids incorporates comprehensive periodontal examination [Hearing Aids J35.7] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Hearing Aids: maintaining Periodontal Pocket Depth in Hearing Aids (J35.7: & Bleeding Index) within Probing <= 3 mm without bleeding (J35.7).
Ask our AI Specialists anything about Hearing Aids
What Is Hearing Aids?
A hearing aid is a small electronic device that you wear in or behind your ear. It makes some sounds louder. A hearing aid can help people hear more in both quiet and noisy situations. Hearing aids help people who have hearing loss from damage to the small sensory cells in the inner ear. The damage can occur as a result of disease, aging, or injury from noise or certain medicines. There are different types of hearing aids. They differ by size, their placement on or inside the ear, and how much they amplify sound. The hearing aid that will work best for you depends on what kind of hearing loss you have and how severe it is.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Hearing Aids (code J35.7) is oropharyngeal tonsillar or in Hearing Aids (J35.7: laryngeal mucosal inflammation), Cross-referenced with NIH MeSH (Hearing Aids), which Ear, Nose, Throat & Oral Health clinicians address while surveilling Periodontal Pocket Depth in Hearing Aids (J35.7: & Bleeding Index) (Probing <= 3 mm without bleeding (J35.7)).
Common Symptoms & Clinical Signs
- • Presentation of Hearing Aids (J35.7): acute earache, sore in Hearing Aids (J35.7: throat with painful)
- • Secondary Hearing Aids clinical sign: episodic spinning vertigo in Hearing Aids (J35.7: accompanied by fluctuating)
- • Symptom flares in Hearing Aids correlating with Periodontal Pocket Depth in Hearing Aids (J35.7: & Bleeding Index) deviation outside Probing <= 3 mm without bleeding (J35.7)
- • Functional ent & hearing impact requiring comprehensive periodontal examination [Hearing Aids J35.7] evaluation (J35.7)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hearing Aids Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J35.7 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Ear, Nose, Throat & Oral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Periodontal Pocket Depth in Hearing Aids (J35.7: & Bleeding Index) | Probing <= 3 mm without bleeding (J35.7) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pure-Tone Audiometry & in Hearing Aids (J35.7: Tympanometry) | Thresholds <= 20 dB HL; normal middle-ear pressure (J35.7) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hearing Aids
Treatment selection for Hearing Aids depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hearing Aids)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Applying a Pharmacometrics-Enabled Machine Learning Analysis to Predict 2-Month Four-week time-to-positivity phase 2a data provided more information compared to the 2-week time-to-positivity data for the prediction of culture conversion. Clinical and translational science • 2026-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42576151 ↗ |
| Can This Approach Help? Inside the Latest Research on Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Long-term high-dose intratympanic dexamethasone treatment did not prevent cisplatin-induced hearing loss. Ear and hearing • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34483247 ↗ |
| Can This Approach Help? Inside the Latest Research on Prophylactic nimodipine treatment improves hearing outcome after vestibular The imbalance in tumor size with larger tumors in females of the treatment group may falsely suggest a gender-related effect. Neurosurgical review • 2021-06-15 • Phase III Randomized Trial | N = 21 | 82/100 | PMID 32827307 ↗ |
Hearing Aids Patient Community & “People Like Me” Threads
Filter Hearing Aids community threads and patient logs by age, biological sex, dosage, and treatment duration.